Moneycontrol PRO
Upcoming Webinar:Join us for 'The Future Techshot' on Sept 22, 10:30am to gain insights into role of tech in streamlining businesses. Register Now!
you are here: HomeNewsBusiness

Drug firms seek free export of Remdesivir as weak demand inflates inventories

Drug makers had ramped up their capacity to make Remdesivir amid acute scarcity during the second wave of the coronavirus pandemic, but demand has crashed in step with the steep fall in the number of new cases.

July 06, 2021 / 01:26 PM IST
Remdesivir is being widely used in treating COVID-19 patients and its demand had skyrocketed following a surge in novel coronavirus infections in India.(Representative image)

Remdesivir is being widely used in treating COVID-19 patients and its demand had skyrocketed following a surge in novel coronavirus infections in India.(Representative image)

  • bselive
  • nselive
Todays L/H

Drug makers have urged the government to remove export curbs on Remdsivir to clear bulging inventories as demand for the anti-viral jab given to hospitalised patients of COVID-19, has fallen sharply.

Manufacturers had aggressively expanded capacity to meet the sudden surge in demand during the second wave of the novel coronavirus pandemic.

"Things are unpredictable during a pandemic like COVID-19. We have expanded capacities responding to the government’s call," said Dharmesh Shah, Chairman of BDR Pharmaceuticals, which manufactures Remdesivir for Cipla.

"The government will have to do a stockpile just to ensure that we are not stranded in case of a third wave. I think the government has done strategic provisioning of the drug, now that there is no demand, it should allow exportation, to allow us clear inventory," Shah added.

In April, the government 'prohibited' the export of Remdesivir. Aware of falling domestic demand on June 14 it moved the drug to 'restricted' category, which means the manufacturers can export the drug but have to get certain clearances from relevant authorities. Manufacturers now want to remove these restrictions as well.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

With adequate supplies all around, some states have cancelled purchase orders worth 4.63 lakh vials in mid June.

Falling demand

Remdesivir is produced by seven companies -- Cipla, Hetero, Cadila Healthcare, Dr Reddy's, Jubilant, Syngene and Mylan in license from US drug maker Gilead. Most of these companies rely on other manufacturers for supply of API and to do fill and finish.

According to the government, domestic production capacity was augmented from 38 lakh vials per month towards the end of March to nearly 122 lakh vials per month with the accelerated approval of 40 additional manufacturing sites by the Drug Controller General of India (DCGI) taking the number of sites to 62.

An official of a company manufacturing Remdesivir told Moneycontrol that they are sitting on a few lakh doses of inventory.

"My phone used to ring all the time, from the states, hospitals and individuals, now I don't get calls anymore because it is freely available," the executive above said.

New COVID-19 cases in India have fallen to less than 40,000 a day from 4 lakh during the peak of the second wave of the pandemic in the first week of May. Remdesivir is given to moderate to severe COVID-19 hospitalised patients. About 10-15 percent of COVID-19 cases end up in hospital. A patient would require 5-6 injections of Remdesivir.

Building buffer

The Centre took over the allocation of Remdesivir on April 21 to ensure fair and equitable distribution across the country for an interim period till production was ramped up and the drug became adequately available in the market.

The government has made a cumulative allocation of 98.87 lakh vials of Remdesivir to states, union territories and Central Health Institutions from April 21 to May 30, 2021. It discontinued the centralised allocation citing decrease in the number of active cases and sufficient availability at the end of the May 2021.

The government, in its latest affidavit filed on June 26 before the Supreme Court, said it had started providing the drug to the states through the central procurement, to build adequate stocks for future contingencies.

"Moreover, close coordination continues to be maintained with manufacturers to maintain adequate stocks of drug and raw materials to enable quick ramp up of production in case of any future sharp surge in demand," the government said.

The Supreme Court is hearing a suo motu writ petition on the government's COVID-19 response.

Follow Moneycontrol’s full coverage of the coronavirus pandemic here
Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
first published: Jul 6, 2021 01:26 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark